title: Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification.
abstract: OBJECTIVE
  To compare bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for the control of postoperative inflammation and prevention of cystoid macular edema (CME) after phacoemulsification.
  
  
  METHODS
  Patients were randomized to receive bromfenac sodium 0.1% for 1 month (OBS1) or 2 months (OBS2), or fluorometholone 0.1% for 1 month (OFM) or dexamethasone 0.1% for 1 month (ODM). Best-corrected visual acuity, intraocular pressure, endothelial cell density, photon count value and retinal foveal thickness were measured.
  
  
  RESULTS
  Mean photon count values were lower in the OBS1 and OBS2 groups compared with the ODM group during the first week. Bromfenac sodium cleared the ocular inflammation more rapidly than fluorometholone and dexamethasone. The foveal thickness was thinner in the second month and the incidence of CME was lower in the OBS1 and OBS2 groups compared with the OFM and ODM groups.
  
  
  CONCLUSIONS
  Bromfenac sodium was more effective and safer than fluorometholone and dexamethasone as an anti-inflammatory, decreasing macular thickness and preventing CME in age-related cataract patients after cataract surgery.
authors: Eye Center, 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, China.
authors: Qi-wei
authors: QW
authors: Wang
authors: Ke
authors: K
authors: Yao
authors: Wen
authors: W
authors: Xu
authors: Pei-qing
authors: PQ
authors: Chen
authors: Xing-chao
authors: XC
authors: Shentu
authors: Xin
authors: X
authors: Xie
authors: Yan
authors: Y
authors: Weng
authors: Li
authors: L
authors: Zhang
authors: Chong-fei
authors: CF
authors: Jin
authors: Wei
authors: W
authors: Wu
authors: Ya-nan
authors: YN
authors: Zhu
authors: Yin-hui
authors: YH
authors: Yu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D001577:Benzophenones / Q000008:administration & dosage*; D001969:Bromobenzenes / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005451:Fluorescein Angiography; D005469:Fluorometholone / Q000008:administration & dosage*; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008269:Macular Edema / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D018918:Phacoemulsification / Q000009:adverse effects*; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D016896:Treatment Outcome; D014605:Uveitis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D003907:Dexamethasone; C053083:bromfenac; D005469:Fluorometholone